Enhanced treatment for hepatitis C could cut prevalence by 80 percent

(Yale University) Novel antiviral therapies for hepatitis C could reduce the prevalence of the blood-borne infection by more than 80 percent, according to an analysis by Yale researchers. The finding raises the possibility of greatly reducing, and even eliminating, hepatitis C in the United States if enhanced screening and treatment efforts target high-risk populations.